Individual Atrasentan Exposure is Associated With Long‐term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease

Atrasentan, an endothelin receptor antagonist, showed clinically significant albuminuria reduction with minimal signs of fluid retention in phase II trials. We evaluated whether plasma exposure was associated with long‐term outcomes for kidney protection and heart failure in the phase III SONAR tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Koomen, Jeroen V., Stevens, Jasper, Bakris, George, Correa‐Rotter, Ricardo, Hou, Fan Fan, Kitzman, Dalane W., Kohan, Donald E., Makino, Hirofumi, McMurray, John J. V., Parving, Hans‐Henrik, Perkovic, Vlado, Tobe, Sheldon W., de Zeeuw, Dick, Heerspink, Hiddo J. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246733/
https://www.ncbi.nlm.nih.gov/pubmed/33338269
http://dx.doi.org/10.1002/cpt.2143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246733/
https://www.ncbi.nlm.nih.gov/pubmed/33338269
http://dx.doi.org/10.1002/cpt.2143

Ejemplares similares